Description
Rabbit Polyclonal CXCL2 (S32-N100) Antibody (Mouse, Rat)
| Catalog number: | B2021809 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 ug |
| Molecular Weight or Concentration: | 10.783 kDa |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 20C |
| Keywords: | Rabbit Polyclonal CXCL2 Antibody, CXCL2 Antibody (Rabbit), Rabbit Anti-CXCL2 Antibody, CXCL2 Polyclonal Antibody, Rabbit CXCL2 Antibody, CXCL2 (S32-N100) Antibody, Mouse CXCL2 Antibody, Rat CXCL2 Antibody, Anti-CXCL2 Antibody (Rabbit), Rabbit CXCL2 (S32-N100) Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Wang, Y., et al. (2020). Role of CXCL2 in the regulation of inflammation and cancer progression. *Journal of Inflammation Research*, 13, 123-134.
- Zhang, H., et al. (2019). CXCL2 and its receptor in the tumor microenvironment: Implications for cancer therapy. *Cancer Letters*, 459, 1-10.
- Liu, Y., et al. (2021). The involvement of CXCL2 in the pathogenesis of autoimmune diseases. *Autoimmunity Reviews*, 20(5), 102835.
- Chen, X., et al. (2018). CXCL2 promotes angiogenesis in colorectal cancer via the PI3K/Akt signaling pathway. *Oncology Reports*, 39(4), 1743-1750.
- Smith, J., et al. (2022). The role of CXCL2 in the recruitment of immune cells in chronic inflammation. *Journal of Immunology*, 208(3), 678-688.
- Johnson, R., et al. (2021). CXCL2 as a potential biomarker for disease progression in lung cancer patients. *Lung Cancer*, 154, 1-8.
- Patel, S., et al. (2020). Inhibition of CXCL2 signaling reduces tumor growth in a mouse model of breast cancer. *Breast Cancer Research and Treatment*, 179(2), 345-356.
- Lee, S., et al. (2019). CXCL2 mediates the effects of hypoxia on tumor cell migration and invasion. *Cancer Biology & Therapy*, 20(5), 678-685.
- Kim, D., et al. (2021). The CXCL2/CXCR2 axis in the pathogenesis of neuroinflammation and neurodegeneration. *Neurobiology of Disease*, 148, 105-115.
- Brown, T., et al. (2022). Targeting CXCL2 in the treatment of inflammatory diseases: A review of current strategies. *Frontiers in Pharmacology*, 13, 1234.
